Xtandi

Chemical Nameenzalutamide
Dosage FormCapsules (oral; 40mg); Tablets (oral; 40mg, 80mg)
Drug ClassInhibitors
SystemMale reproductive
CompanyAstellas Pharma Inc.
Approval Year2012

Indication

  • For the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xtandi (enzalutamide) Prescribing Information2012Astellas Pharma US Inc., Northbrook, IL
Document TitleYearSource
Apalutamide, enzalutamide, and darolutamide for non‑metastatic castration‑resistant prostate cancer: a systematic review and network meta‑analysis.2020International Journal of Clinical Oncology
Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. 2020European Urology
Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. 2020Prostate Cancer and Prostatic Diseases
A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.2020Clinical Genitourinary Cancer
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. 2020Journal of Oncology Pharmacy Practice
Systemic management for non-metastatic castration-resistant prostate cancer. 2020American Journal of Clinical Oncology
Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. 2020Prostate Cancer and Prostatic Diseases
Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis.2020Journal of Pharmacy and Pharmaceutical Sciences
Comparative efficacy of combined radiotherapy, systemic therapy, and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: A network meta-analysis and systematic review.2020Frontiers in Oncology
Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer.2019Medicine
Third-line treatment and 177Lu-PSMA radio ligand therapy of metastatic castration-resistant prostate cancer: a systematic review.2018European Journal of Nuclear Medicine and Molecular Imaging
Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer.2018Value in Health
Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration‑resistant prostate cancer: a systematic review.2017Asian Journal of Andrology
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. 2017Current Medical Research and Opinion
First‐line non‐cytotoxic therapy in chemotherapy‐naive patients with metastatic castration‐resistant prostate cancer: a systematic review of 10 randomised clinical trials. 2017BJU International
Document TitleYearSource
EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. 2021European Association of Urology
Prostate cancer, version 2.2019.2019Journal of the National Comprehensive Cancer Network